kempten
![]()
Posts:128
Hello
I listened to an older video by Dr Jack West ( 2013) who said at the time, that the handful of patients he put on Afitinib at that point had disappointing results.
Is Afitinib still a useful drug as second line treatment for EGFR positive adenocarcinoma that has progressed on Tarceva , or should one go right to Tagrisso.
Tagrisso was just approved.
What can we expect in terms of it being covered by most health insurances?
Thanks
Kempten
Forums
Reply # - November 17, 2015, 02:49 PM
That's great news about
That's great news about tagrisso being approved. Tagrisso is approved for EGFR mutant lung cancer with T790M mutations so should be readily approved by insurance in the US.
Afitinib still appears to be less beneficial than 3rd gen options.
Best for you and yours Kempten,
Janine